108 related articles for article (PubMed ID: 849997)
21. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
[TBL] [Abstract][Full Text] [Related]
22. Absolute bioavailability of oral theophylline.
Hendeles L; Weinberger M; Bighley L
Am J Hosp Pharm; 1977 May; 34(5):525-7. PubMed ID: 868891
[TBL] [Abstract][Full Text] [Related]
23. Comparative bio-availability of theophylline whole and halved sustained-release tablets.
Müller FO; Hundt HK; Luus HG; van Dyk M; Groenewoud G; van der Meer MJ; Steinijans VW
S Afr Med J; 1987 Aug; 72(3):175-8. PubMed ID: 3299763
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of circadian variation of serum theophylline concentration and bioavailability between Theo-dur tablet and a new sustained-release theophylline formulation (E-0686 granule)].
Kishida M; Okuma M; Uekusa T; Akimoto K; Obata T; Akazawa A; Odajima Y; Nagakura T; Iikura Y; Hukushima K
Arerugi; 1988 Apr; 37(4):218-25. PubMed ID: 3228360
[No Abstract] [Full Text] [Related]
25. Comparison of steady state serum theophylline concentrations in healthy volunteers after dosing with Euphyllin retard and PulmiDur.
Karlsson S; Lührmann B; Bahner ML; Schulz HU
Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):342-6. PubMed ID: 3623739
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetics of dihydroxypropyltheophylline: a basis for rational therapy.
Simons FE; Simons KJ; Bierman CW
J Allergy Clin Immunol; 1975 Nov; 56(5):347-55. PubMed ID: 1181352
[TBL] [Abstract][Full Text] [Related]
27. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
28. Serum theophylline levels in asthmatic children receiving sustained-release theophylline tablets.
Kelly HW; Murphy S
Am J Hosp Pharm; 1979 Dec; 36(12):1698-701. PubMed ID: 525646
[TBL] [Abstract][Full Text] [Related]
29. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
González MA; Straughan AB
Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
[TBL] [Abstract][Full Text] [Related]
30. Theophylline and dyphylline pharmacokinetics in the horse.
Ayres JW; Pearson EG; Riebold TW; Chang SF
Am J Vet Res; 1985 Dec; 46(12):2500-6. PubMed ID: 4083583
[TBL] [Abstract][Full Text] [Related]
31. Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.
Lagas M; Jonkman JH
Eur J Clin Pharmacol; 1983; 24(6):761-7. PubMed ID: 6884413
[TBL] [Abstract][Full Text] [Related]
32. Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24 capsules.
Jonkman JH; Steinijans VW; Beier W; van der Boon WJ; Crasmeijer G
Biopharm Drug Dispos; 1989; 10(2):213-24. PubMed ID: 2706320
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets.
Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715
[TBL] [Abstract][Full Text] [Related]
34. Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of a controlled release tablet.
Lagas M; Jonkman JH
Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):424-6. PubMed ID: 4044074
[TBL] [Abstract][Full Text] [Related]
35. A new sustained-release theophylline suspension for asthmatic children: evaluation of serum theophylline concentrations.
Boner AL; Vallone G; Valletta E; Bernocchi D; Plebani M
Int J Clin Pharmacol Res; 1987; 7(5):345-50. PubMed ID: 3667007
[TBL] [Abstract][Full Text] [Related]
36. Relative bioavailability of oral sustained-release and regular-release oxprenolol tablets at steady-state.
Gupta PK; Lim JK; Zoest AR; Lam FC; Hung CT
Biopharm Drug Dispos; 1991 Oct; 12(7):493-503. PubMed ID: 1932612
[TBL] [Abstract][Full Text] [Related]
37. Hydrophilic thermoplastic polyurethanes for the manufacturing of highly dosed oral sustained release matrices via hot melt extrusion and injection molding.
Verstraete G; Van Renterghem J; Van Bockstal PJ; Kasmi S; De Geest BG; De Beer T; Remon JP; Vervaet C
Int J Pharm; 2016 Jun; 506(1-2):214-21. PubMed ID: 27113866
[TBL] [Abstract][Full Text] [Related]
38. Nocturnal asthma: effect of a once per evening dose of sustained release theophylline.
Neuenkirchen H; Wilkens JH; Oellerich M; Sybrecht GW
Eur J Respir Dis; 1985 Mar; 66(3):196-204. PubMed ID: 3884358
[TBL] [Abstract][Full Text] [Related]
39. Absorption characteristics of once-a-day slow-release theophylline preparation in children with asthma.
Pedersen S; Steffensen G
J Pediatr; 1987 Jun; 110(6):953-9. PubMed ID: 3585612
[TBL] [Abstract][Full Text] [Related]
40. Bioavailability and efficacy of a sustained-release theophylline tablet.
Mitenko PA; Ogilvie RI
Clin Pharmacol Ther; 1974 Oct; 16(4):720-6. PubMed ID: 4609343
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
